Scarica l'app Stockscreener
25.14
0.40%
0.10
Dopo l'orario di chiusura:
25.14
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché APLS Giù?
Forum
Previsione
Precedente Chiudi:
$25.04
Aprire:
$25.05
Volume 24 ore:
1.31M
Relative Volume:
0.71
Capitalizzazione di mercato:
$3.16B
Reddito:
$715.22M
Utile/perdita netta:
$-250.10M
Rapporto P/E:
-12.38
EPS:
-2.03
Flusso di cassa netto:
$-205.58M
1 W Prestazione:
+4.49%
1M Prestazione:
-12.34%
6M Prestazione:
-35.83%
1 anno Prestazione:
-59.21%
Intervallo 1D:
$24.48
$25.44
Intervallo di 1 settimana:
$24.43
$26.15
Portata 52W:
$23.81
$63.07
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Nome
Apellis Pharmaceuticals Inc
Settore
Industria
Telefono
617-977-5700
Indirizzo
100 FIFTH AVENUE, WALTHAM, KY
Confronta APLS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
25.14 | 3.16B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.01 | 128.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
744.83 | 81.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
571.00 | 34.69B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
233.07 | 30.17B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
242.66 | 26.02B | 3.32B | -860.46M | -1.04B | -8.32 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-17 | Downgrade | Goldman | Buy → Neutral |
| 2024-11-21 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-10-25 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-10-16 | Iniziato | William Blair | Outperform |
| 2024-05-31 | Iniziato | Piper Sandler | Neutral |
| 2024-02-05 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-12-14 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | Iniziato | Goldman | Buy |
| 2023-11-02 | Iniziato | Mizuho | Neutral |
| 2023-10-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-09-15 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | Reiterato | Citigroup | Buy |
| 2023-08-03 | Downgrade | JP Morgan | Overweight → Neutral |
| 2023-08-01 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-01-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-19 | Iniziato | H.C. Wainwright | Buy |
| 2022-06-17 | Ripresa | Stifel | Buy |
| 2022-04-14 | Downgrade | ROTH Capital | Neutral → Sell |
| 2021-12-08 | Iniziato | Wells Fargo | Overweight |
| 2021-11-29 | Downgrade | ROTH Capital | Buy → Neutral |
| 2021-09-10 | Reiterato | BMO Capital Markets | Outperform |
| 2021-09-10 | Reiterato | Credit Suisse | Neutral |
| 2021-09-10 | Reiterato | Needham | Buy |
| 2021-09-10 | Reiterato | Oppenheimer | Outperform |
| 2021-09-10 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-08-19 | Iniziato | Jefferies | Buy |
| 2021-08-19 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-16 | Iniziato | Goldman | Buy |
| 2020-11-19 | Iniziato | Needham | Buy |
| 2020-09-01 | Iniziato | Stifel | Buy |
| 2020-07-20 | Iniziato | ROTH Capital | Buy |
| 2020-06-17 | Iniziato | BTIG Research | Neutral |
| 2020-04-01 | Iniziato | Raymond James | Strong Buy |
| 2020-03-31 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-11 | Aggiornamento | Wedbush | Underperform → Neutral |
| 2020-01-07 | Iniziato | SVB Leerink | Mkt Perform |
| 2019-12-19 | Iniziato | BofA/Merrill | Buy |
| 2019-11-22 | Iniziato | Wedbush | Underperform |
| 2019-11-05 | Iniziato | Credit Suisse | Neutral |
| 2019-08-01 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-03-29 | Iniziato | Robert W. Baird | Outperform |
| 2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-07-30 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-04-12 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | Iniziato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Apellis Pharmaceuticals Inc Borsa (APLS) Ultime notizie
Learn to Evaluate (APLS) using the Charts - Stock Traders Daily
Apellis Pharmaceuticals general counsel sells shares for $139,789 By Investing.com - Investing.com South Africa
Apellis Pharmaceuticals general counsel sells shares for $139,789 - Investing.com India
Compared to Estimates, Apellis Pharmaceuticals (APLS) Q4 Earnings: A Look at Key Metrics - MSN
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Apellis Q4 Loss Narrower Than Expected, Syfovre Sales Drive Revenues - MSN
Apellis Pharmaceuticals: A Mixed Bag (NASDAQ:APLS) - Seeking Alpha
Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst - Benzinga
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q4 2024 Earnings Call Transcript - MSN
JPMorgan Chase & Co. Issues Positive Forecast for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price - Defense World
Apellis Pharmaceuticals Faces Financial Challenges Amid Ambitious Drug Commercialization Efforts - MSN
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Cut to $29.00 by Analysts at Wedbush - Defense World
Apellis Pharmaceuticals’ (APLS) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Lowered to $32.00 at The Goldman Sachs Group - Defense World
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Lowered to $25.00 at Royal Bank of Canada - Defense World
Apellis Class Action: Levi & Korsinsky Reminds Apellis Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 2, 2023 – APLS - ACCESS Newswire
Breaking Down Apellis Pharmaceuticals: 6 Analysts Share Their Views - Benzinga
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Apellis Pharmaceuticals, Inc.(APLS) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
New York State Common Retirement Fund Sells 327,776 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Apellis Pharmaceuticals, Inc. (APLS) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
SHAREHOLDER ALERT: Potential Recovery for Apellis Pharmaceuticals, Inc. (APLS) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Loss, Tops Revenue Estimates - MSN
Apellis Pharmaceuticals (NASDAQ:APLS) Hits New 52-Week Low – What’s Next? - Defense World
SHAREHOLDER ALERT: Potential Recovery for Apellis Pharmaceuticals, Inc. (APLS) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Decoding Apellis Pharmaceuticals Inc (APLS): A Strategic SWOT In - GuruFocus.com
Apellis Pharmaceuticals Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
Apellis Pharmaceuticals CFO sells shares worth $93,953 - MSN
Apellis Pharmaceuticals Inc (APLS) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and ... - Yahoo Finance
Apellis Pharmaceuticals' chief business officer sells $10,359 in stock - MSN
Apellis Pharmaceuticals Reports Strong 2024 Growth - TipRanks
Apellis Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Apellis Pharmaceuticals: Strong Buy Rating Maintained Amid Market Share Adjustments - TipRanks
Apellis Pharma stock hits 52-week low at $24.34 amid market challenges - Investing.com Australia
Apellis Pharmaceuticals reports Q4 revenue beat, shares fall on Syfovre guidance - Investing.com Australia
Apellis Pharma stock hits 52-week low at $24.34 amid market challenges By Investing.com - Investing.com South Africa
Earnings call transcript: Apellis Pharmaceuticals Q4 2024 sees revenue surge - Investing.com
Earnings call transcript: Apellis Pharmaceuticals Q4 2024 sees revenue surge By Investing.com - Investing.com South Africa
Apellis Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Why Apellis Pharmaceuticals Shares Are in Flux - TipRanks
Earnings Flash (APLS) Apellis Pharmaceuticals Posts Q4 Net Loss $-0.29 a Share, vs. FactSet Est of $-0.37 Loss - Marketscreener.com
APELLIS PHARMACEUTICALS Earnings Results: $APLS Reports Quarterly Earnings - Nasdaq
Earnings Flash (APLS) Apellis Pharmaceuticals Posts Q4 Revenue $212.5M, vs. FactSet Est of $198.8M - Marketscreener.com
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Apellis Pharmaceuticals Q4 Net Loss Narrows, Revenue Rises -February 28, 2025 at 07:28 am EST - Marketscreener.com
What To Expect From Apellis Pharmaceuticals Inc (APLS) Q4 2024 E - GuruFocus.com
Apellis Pharmaceuticals Inc Azioni (APLS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.98%
8.97%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):